Jago Times "English Edition" Best Online Newspaper
People with mild-to-moderate COVID-19 who were treated with a monoclonal antibody “cocktail” had lower hospitalization rates than similar people who did not receive the treatment, researchers reported on Monday in EClinicalMedicine.
They looked at nearly 1,400 such patients, roughly half of whom had received Regeneron Pharmaceutical’s combination monoclonal antibody therapy. Among those who received the treatment, about 45% were older than 65, and many had high blood pressure, obesity, diabetes, lung disease and other risk factors.
By four weeks after the treatment, 1.6% of them had been hospitalized, compared to 4.8% of patients not treated with the monoclonal antibodies.
The study was not randomized and cannot prove the treatment caused the better outcomes.
However, it “suggests that when patients who are at high risk due to a range of comorbidities contract a mild or moderate case of COVID-19, this combination of monoclonal injections gives them a chance of a nonhospitalized recovery,” study leader Dr. Raymund Razonable of the Mayo Clinic in Rochester, Minnesota in a statement.
The Regeneron anitbody cocktail, known as REGEN-COV, is authorized for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
Limitations of Authorized Use
REGEN-COV is not authorized for use in patients who are hospitalized due to COVID-19, or who require oxygen therapy due to COVID-19, or who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity.
Monoclonal antibodies, such as REGEN-COV, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high-flow oxygen or mechanical ventilation